Free Demo Kit
In The News
 |
 |
The press is talking about OmniPod.
Often, newspapers, magazines and other print publications choose to feature the OmniPod and the people who use it. When possible, we archive these articles for your perusal. Simply click the links below to read more.
Please note, you must have Adobe® Acrobat Reader® on your computer to view many of these articles. If you do not have this software, you can download a free copy.
Siphon Effects of Continuous Subcutaneous Insulin Infusion Pump Delivery Performance
Journal of Diabetes Science and Technology, 2010
Researchers tested three conventional pumps (with tubing) along with the OmniPod to quantify the siphon effects in the tubing with continuous subcutaneous insulin infusion (CSII) during basal and bolus insulin delivery. This study demonstrated that changing the position of a conventional CSII pump in relation to the infusion site results in significant changes in insulin delivery especially during low bolus rates.
Copyright © 2010 Diabetes Technology Society
Reprinted with permission from Diabetes Technology Society.
Clinical Experience with a Tubing-Free Insulin Pump System
Infusystems USA, 2009
A retrospective, 1 year study of clinical experience with the OmniPod System in patients with both Type 1 and Type 2 diabetes and who had previously been on either MDI or pump therapy with a conventional pump. The study showed that the OmniPod system demonstrated improvements in glycemic control with patients previously on MDI.
Copyright © 2009 Infusystems USA
Reprinted with permission from Infusystems USA.
Diabetes Technology & Therapeutics, 2009
Researchers at the University of California Santa Barbara, Sansum Diabetes Research Institute and Stanford Medical Center successfully created a computer-simulated system to evaluate an artificial pancreas. The “pancreas” is comprised of the OmniPod System and a continuous glucose monitor, governed by an algorithm. The study, funded by the JDRF, streamlines preclinical validation trials, bringing the artificial pancreas closer to reality.
From Diabetes Technology & Therapeutics, Vol 11, 2009; 187-194.
One Road to Hope: JDRF’s Artificial Pancreas Project at the University of Virginia
In this video, found on the JDRF site, researchers at the University of Virginia Health System, patients and diabetes advocates describe the JDRF Artificial Pancreas Project and its potential impact; then one patient documents his experiences with the clinical trial.
This video was made for research purposes only. Insulet makes no real or implied claims concerning the suitability of this technology for diabetes management using the OmniPod Diabetes Management System.
November 2008
This HealthMatters story on the history of insulin pumps features Ironwoman Triathlete and OmniPod user Kathy Gagnier. Kathy finds that pump therapy makes her diabetes easier to manage. Note: Kathy personalizes the look of all of her pods with permanent markers. Used by permission of HealthMatters For People With Diabetes and Liberty Medical.
Positive Update: Adventure Photographer Lisa Seaman
March 2008
Diabetes Positive! profiles outdoorswoman and adventure photographer Lisa Seaman. An enthusiastic pumper, Lisa recently switched to OmniPod—and she talks about how the System helps her lead her active lifestyle.
Sky Radio interview with Shawna Gvazdauskas
March 2008
Sky Radio—renowned producers of business, technology and health programming for the airlines and internet—spoke with Insulet’s then Senior Vice President of Sales & Marketing Shawna Gvazdauskas about how the OmniPod System works, and how it is making diabetes a smaller part of life for thousands.
Quantifying the Impact of a Short-Interval Interruption of Insulin-Pump Infusion Sets on Glycemic Excursions
Diabetes Care, 2008
A prospective, open-label study measured the impact of short-term infusion set disconnects on glucose levels. It shows that even short-term interruption of insulin delivery can cause blood glucose levels to rise and remain elevated for hours post-interruption.
Copyright © 2008 American Diabetes Association
From Diabetes Care®, Vol. 31, 2008; 238-239
Reprinted with permission from The American Diabetes Association.
The OmniPod Insulin Management System
November 2007
In a cover story, Diabetes Positive! explores the history of the OmniPod and its advantages over conventional pumps—including its lower start-up costs. Interviewee Anthony Vita notes that the System “has given [him] back [his] life.”
Insulet signs deal to ramp up insulin pump supply
October 4, 2007
Reuters reports that a new deal with Flextronics, one of the largest suppliers of blood glucose meters, will boost Insulet’s production capacity; it further speculates that the OmniPod System’s relative convenience may help encourage more people with Type 2 diabetes to use insulin pumps.
diaTribe: Test Driving Insulet’s OmniPod System
May/June 2007
diaTribe columnist Kelly Close describes her experience with OmniPod, including details of how the System works and how she compares it to other pumps she has used. Close’s conclusion: She would sacrifice her cell phone for an OmniPod.
OmniPod Insulin Management System: Patient perceptions, preference and glycemic control
Diabetes Care, 2006
Diabetes researchers Howard Zisser, MD and Lois Jovanovic, MD detail the results of a 30-day study comparing the OmniPod with conventional insulin pump therapy along metrics of glycemic control, convenience, insertion pain and satisfaction. Subjects showed remarked preference for the OmniPod; importantly, they also showed significantly reduced A1C values.
Copyright © 2006 American Diabetes Association
From Diabetes Care®, Vol. 29, 2006; 2175
Reprinted with permission from The American Diabetes Association.
A ‘Gadget Guy’ Embraces Diabetes
July 2006
Diabetes Health interviews The Diabetic Investor editor David Kliff, on life with the OmniPod System, including his lower A1Cs and the freedom of having no tubing.
Insulin Pump Therapy: A meta-analysis
Diabetes Care, 2003
Examining the metabolic and psychosocial impact of insulin pump therapy, this study concluded that insulin pumps improve glycemic control as compared with other therapies.
Copyright © 2003 American Diabetes Association
From Diabetes Care®, Vol. 26, 2003; 1079-1087
Reprinted with permission from The American Diabetes Association.
Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Regimens Using Insulin Lispro in Type 1 Diabetic Patients on Intensified Treatment
Diabetes Care, 2000
A randomized study compared the efficacy of two treatment regimes: continuous subcutaneous insulin infusion (insulin pump therapy) and multiple daily injections (MDI). Subjects using insulin pumps achieved much better glycemic control using less insulin than subjects using MDI.
Copyright © 2000 American Diabetes Association
From Diabetes Care®, Vol. 23, 2000; 1232-1235
Reprinted with permission from The American Diabetes Association.
Reduction in Severe Hypoglycemia With Long-Term Continuous Subcutaneous Insulin Infusion in Type I Diabetes
Diabetes Care, 1996
This study compared the incidence of severe hypoglycemia in patients who switched to continuous subcutaneous insulin infusion (CSII) from multiple daily injections (MDI). It concluded that CSII therapy produced a “marked and sustained reduction” in hypoglycemia, due to the reproducible and flexible insulin delivery.
Copyright © 1996 American Diabetes Association
From Diabetes Care®, Vol. 19, 1996; 324-327
Reprinted with permission from The American Diabetes Association.
Join PodWatch™
Contact Information
Privacy Policy
Terms of Use
© 2010 Insulet Corporation. All rights reserved.
Content in MyOmniPod.com is intended for residents of the United States (and Puerto Rico) only.
As a result, the site may contain information about products or uses of those products, and promotional offers that are not approved in other countries. If you are a resident of a country other than the United States, please visit the International section of this site to obtain the appropriate information for your country of residence.